Michelangelo Marasco

Michelangelo Marasco

Auto-generated profile, based on publicly available information

Michelangelo Marasco

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MMM. Marasco
M. Marasco
ABA. Berteotti
A. Berteotti
JWJ. Weyershaeuser
J. Weyershaeuser
NTN. Thorausch
N. Thorausch
JSJ. Sikorska
J. Sikorska
TCTeresa Carlomagno
Teresa Carlomagno
One is not enough: Two PD-1 pTyr motifs bind to SHP2 simultaneously, inducing a conformational change and phosphatase activation.

10 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RYRona Yaeger
Rona Yaeger
RMRiccardo Mezzadra
Riccardo Mezzadra
JSJenna Sinopoli
Jenna Sinopoli
YBYu Bian
Yu Bian
MMMichelangelo Marasco
Michelangelo Marasco
SMSandra Misale
Sandra Misale
With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alterations expected primarily to prevent inhibition of ERK signaling by drugs at progression. Serial analysis of patient blood samples on treatment demonstrates that most of these alterations are detected at a low frequency except for KRASG12C amplification, a recurrent resistance mechanism that rises in step with clinical progression. Upon drug withdrawal, resistant cells with KRASG12C amplification undergo oncogene-induced senescence, and progressing patients experience a rapid fall in levels of this alteration in circulating DNA. In this new state, drug resumption is ineffective as mTOR signaling is elevated. However, our work exposes a potential therapeutic vulnerability, whereby therapies that target the senescence response may overcome acquired resistance. Significance: Clinical resistance to KRASG12C–EGFR inhibition primarily prevents suppression of ERK signaling. Most resistance mechanisms are subclonal, whereas KRASG12C amplification rises over time to drive a higher portion of resistance. This recurrent resistance mechanism leads to oncogene-induced senescence upon drug withdrawal and creates a potential vulnerability to senolytic approaches. Watch the interview with Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award: https://vimeo.com/1100471486 This article is highlighted in the In This Issue feature, p. 1

1 January 2020 in Journal of Structural Biology: X
Verified
Journal Article
Open access
MMMichelangelo Marasco
Michelangelo Marasco
TCTeresa Carlomagno
Teresa Carlomagno
• By specifically recognizing phosphotyrosine-containing motifs, SH2 domains modulate a variety of essential cellular processes. • Despite their very conserved fold, SH2 domains have achieved a high level of specificity, while ensuring fast response times to changing cellular conditions. • The conventional view of cellular signaling centered around enthalpy-based equilibrium descriptors cannot account for such a degree of specificity. • Only an integrated view of structural biology, thermodynamics, binding kinetics and protein dynamics can successfully address the specificity mechanisms of SH2 domains.

28 April 2025 in Cancer Discovery
Verified
Journal Article
Closed access
MMMichelangelo Marasco
Michelangelo Marasco
DKDinesh Kumar
Dinesh Kumar
SBSantiago Garcia Borrego
Santiago Garcia Borrego
TSTessa Seale
Tessa Seale
GMGiulia Maddalena
Giulia Maddalena
SMSandra Misale
Sandra Misale
RAS genes are frequently mutated in cancer, often at codons 12 and 61. With the recent introduction of RAS inhibitors, we can now directly investigate the effects of specific RAS mutations in cancer cells. In this study, we demonstrate that in tumors with RASG12X mutations, mutant RAS can be activated by receptor tyrosine kinases (RTK), and PI3K activation is dependent on mutant RAS. Conversely, RASQ61X mutations activate the MAPK cascade independently of RTKs, and inhibition of RASQ61X impairs MAPK pathway activation but leaves the PI3K pathway unaffected. Our characterization of these distinct features of G12X and Q61X mutations suggests that co-inhibition of RAS and RTKs selectively inhibits the growth of RASG12X-mutant tumors, both in vitro and in vivo, regardless of the RAS isoform and tumor type. Additionally, our findings offer a mechanistic explanation for the increased frequency of RASQ61X mutations as a secondary resistance mechanism against EGFR inhibition in colorectal cancer. Significance: RAS inhibition in multiple tumor types reveals the difference between G12 mutants and Q61 mutants in their cooperation with upstream regulators and downstream effectors to promote oncogenic signaling. Our findings provide the rationale for combinatorial approaches and contribute to explaining the nonuniform distribution of RAS mutations, de novo and at resistance.

4 May 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
MMMichelangelo Marasco
Michelangelo Marasco
JKJohn Kirkpatrick
John Kirkpatrick
TCTeresa Carlomagno
Teresa Carlomagno
JHJochen S. Hub
Jochen S. Hub
MAMassimiliano Anselmi
Massimiliano Anselmi
We have determined the heterogeneous structural ensemble of the tandem SH2 domains of the protein tyrosine phosphatase SHP2 in agreement with experimental data from small-angle X-ray scattering and NMR residual dipolar couplings in solution.

18 June 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NSNaira Samarina
Naira Samarina
GSGeorge Ssebyatika
George Ssebyatika
TTTanvi Tikla
Tanvi Tikla
JWJa-Yun Waldmann
Ja-Yun Waldmann
BABizunesh Abere
Bizunesh Abere
TSThomas Schultz
Thomas Schultz
Kaposi Sarcoma-associated herpesvirus (KSHV) causes three human malignancies, Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL) and the plasma cell variant of multicentric Castleman’s Disease (MCD), as well as an inflammatory cytokine syndrome (KICS). Its non-structural membrane protein, pK15, is among a limited set of viral proteins expressed in KSHV-infected KS tumor cells. Following its phosphorylation by Src family tyrosine kinases, pK15 recruits phospholipase C gamma 1 (PLCγ1) to activate downstream signaling cascades such as the MEK/ERK, NFkB and PI3K pathway, and thereby contributes to the increased proliferation and migration as well as the spindle cell morphology of KSHV-infected endothelial cells. Here, we show that a phosphorylated Y481EEVL motif in pK15 preferentially binds into the PLCγ1 C-terminal SH2 domain (cSH2), which is involved in conformational changes occurring during the activation of PLCγ1 by receptor tyrosine kinases. We determined the crystal structure of a pK15 12mer peptide containing the phosphorylated pK15 Y481EEVL motif in complex with a shortened PLCγ1 tandem SH2 (tSH2) domain. This structure demonstrates that the pK15 peptide binds to the PLCγ1 cSH2 domain in a position that is normally occupied by the linker region connecting the PLCγ1 cSH2 and SH3 domains. We also show that longer pK15 peptides containing the phosphorylated pK15 Y481EEVL motif can increase the Src-mediated phosphorylation of the PLCγ1 tSH2 region in vitro. This pK15-induced increase in Src-mediated phosphorylation of PLCγ1 can be inhibited with the small pK15-derived peptide which occupies the PLCγ1 cSH2 domain. Our findings thus suggest that pK15 may act as a scaffold protein to promote PLCγ1 activation in a manner similar to the cellular scaffold protein SLP-76, which has been shown to promote PLCγ1 activation in the context of T-cell receptor signaling. Reminiscent of its positional homologue in Epstein-Barr Virus, LMP2A, pK15 may therefore mimic aspects of antigen-receptor signaling. Our findings also suggest that it may be possible to inhibit the recruitment and activation of PLCγ1 pharmacologically.